Targeted therapies directed to tumor-associated antigens

Drugs of the Future

Volumn 30, Issue 10, 2005, Pages 1067-1076

  Everts, Maaike ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIBODY; ANTIMETABOLITE; CETUXIMAB; CHEMICAL AGENT; CISPLATIN; CYTOKINE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LIGAND; LIPOSOME; MACROGOL; METHOTREXATE; NAKED DNA; NANOPARTICLE; ONZAR; PEPTIDE DERIVATIVE; PSEUDOMONAS EXOTOXIN; RADIOISOTOPE; RITUXIMAB; TOXIN; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; COLON CANCER; DRUG EFFICACY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; SKIN CANCER; TARGET ORGAN; TECHNIQUE;

EID: 30744475440     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.10.933191     Document Type: Review

References (100)

1. Kosterink, J.G.W., Helfrich, W., de Leij, L.F.M.H. Strategies for specific drug targeting to tumor cells. In: Drug Targeting, Organ-Specific Strategies. G. Molema, D.K.F. Meijer (Eds.). Wiley-VCH, Weinheim, 2001, 199-231.
2. Gold, P., Freedman, S.O. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965, 122: 467-81.
3. Hammarstrom, S. The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9: 67-81.
4. Taylor, D.D., Black, P.H. Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol (NY 1985) 1986, 3: 33-57.
5. Wong, J.Y., Chu, D.Z., Williams, L.E. et al. Pilot trial evaluating an 1231-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (Ct84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004, 10: 5014-21.
6. Suresh, M.R. Classification of tumor markers. Anticancer Res 1996, 16: 2273-7.
7. Coscia, M., Kwak, L.W. Therapeutic idiotype vaccines in B lymphoproliferative diseases. Exp Opin Biol Ther 2004, 4: 959-63.
8. Bendandi, M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Exp Rev Vaccines 2004, 3: 163-70.
9. Ford, A.C., Grandis, J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003, 25: 67-73.
10. Morris, C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat 2002, 75(Suppl. 1): S51-5; discussion S57-9.
11. Harlozinska, A., Bar, J.K., Sobanska, E., Goluda, M. Epidermal growth factor receptor and C-ErbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumour Biol 1998, 19: 364-73.
12. Carlsson, J., Nordgren, H., Sjostrom, J. et al. Her2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004, 90: 2344-8.
13. Christensen, J.G., Burrows, J., Salgia, R. C-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005, 225: 1-26.
14. Karsten, U., von Mensdorff-Pouilly, S., Goletz, S. What makes Muc1 a tumor antigen? Tumour Biol 2005, 26: 217-20.
15. Moore, A., Medarova, Z., Potthast, A., Dai, G. In vivo targeting of underglycosylated Muc-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004, 64: 1821-7.
16. Welsh, J.B., Sapinoso, L.M., Su, A.I. et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001, 61: 5974-8.
17. Welsh, J.B., Zarrinkar, P.P., Sapinoso, L.M. et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001, 98: 1176-81.
18. Omenn, G.S. The Human Proteome Organization Plasma Proteome Project Pilot Phase: Reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004, 4: 1235-40.
19. Nishizuka, S., Chen, S.T., Gwadry, F.G. et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003, 63: 5243-50.
20. Sahin, U., Tureci, O., Schmitt, H. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995, 92: 11810-3.
21. Li, G., Miles, A., Line, A., Rees, R.C. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004, 53: 139-43.
22. Daniels, D.A., Chen, H., Hicke, B.J. et al. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 2003, 100: 15416-21.
23. Schmidt, K.S., Borkowski, S., Kurreck, J. et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 2004, 32: 5757-65.
24. Kohler, G., Milstein, C. Continuous cultures of fused cells-secreting antibody of predefined specificity. Nature 1975, 256: 495-7.
25. Clark, M. Antibody humanization: A case of the emperor's new clothes'? Immunol Today 2000, 21: 397-402.
26. Batra, S.K., Jain, M., Wittel, U.A. et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002, 13: 603-8.
27. Kuan, C.T., Wikstrand, C.J., Archer, G. et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 2000, 88: 962-9.
28. Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228: 1315-7.
29. Peletskaya, E.N., Glinsky, G., Deutscher, S.L., Quinn, T.P. Identification of peptide sequences that bind the Thomsen-Friedenreich cancer-associated glycoantigen from bacteriophage peptide display libraries. Mol Divers 1996, 2: 13-8.
30. Peletskaya, E.N., Glinsky, V.V., Glinsky, G.V. et al. Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. J Mol Biol 1997, 270: 374-84.
31. Koivunen, E., Gay, D.A., Ruoslahti, E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993, 268: 20205-10.
32. Schiffelers, R.M., Koning, G.A., ten Hagen, T.L. et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003, 91: 115-22.
33. Dmitriev, I., Krasnykh, V., Miller, C.R. et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 72: 9706-13.
34. Shi, W., Bartlett, J.S. RGD inclusion in Vp3 provides adeno-associated virus type 2 (Aav2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 2003, 7: 515-25.
35. Douglas, J.T., Rogers, B.E., Rosenfeld, M.E. et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996, 14: 1574-8.
36. Reddy, J.A., Allagadda, V.M., Leamon, C.P. Targeting therapeutic and imaging agents to Mate receptor positive tumors. Curr Pharm Biotechnol 2005, 6: 131-50.
37. Bohl Kullberg, E., Bergstrand, N., Carlsson, J. et al. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem 2002, 13: 737-43.
38. Dmitriev, I., Kashentseva, E., Rogers, B.E. et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000, 74: 6875-84.
39. Molema, G. Drug targeting: Basic concepts and novel advances. In: Drug Targeting. Organ-Specific Strategies. G. Molema, D.K.F. Meijer (Eds.). Wiley-VCH, Weinheim, 2001, 1-22.
40. Storm, G., Crommelin, D.J. Colloidal systems for tumor targeting: Hybridoma 1997, 16: 119-25.
41. Gabizon, A., Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997, 54(Suppl. 4): 15-21.
42. Brignole, C., Marimpietri, D., Gambini, C. et al. Development of Fab' fragments of anti-Gd(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett 2003, 197: 199-204.
43. Park, J.W., Benz, C.C., Martin, F.J. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004, 31: 196-205.
44. Kukowska-Latallo, J.F., Candido, K.A., Cao, Z. et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005, 65: 5317-24.
45. Loo, C., Lowery, A., Halas, N. et al. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 2005, 5: 709-11.
46. Everts, M., Kim-Park, S.A., Preuss, M. et al. Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. Gene Ther 2005, Advance online publication.
47. Hedley, S.J., Auf der Maur, A., Hohn, S. et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2005, In press.
48. Nakamura, T., Peng, K.W., Harvey, M. et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005, 23: 209-14.
49. Chaudhary, V.K., Gallo, M.G., FitzGerald, D.J., Pastan, I. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc Natl Acad Sci USA 1990, 87: 9491-4.
50. Peng, L.S., Penichet, M.L., Morrison, S.L. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J Immunol 1999, 163: 250-8.
51. Blum, K.A., Bartlett, N.L. 90Yttrium-ibritumomab tiuxetan: A novel treatment for non-Hodgkin's lymphoma. Exp Opin Biol Ther 2004, 4: 1323-31.
52. Lode, H.N., Reisfeld, R.A., Handgretinger, R. et al. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res 1998, 58: 2925-8.
53. Kok, R.J., Asgeirsdottir, S.A., Verweij, W.R. Development of proteinaceous drug targeting constructs using chemical and recombinant DNA approaches. In: Drug Targeting, Organ-Specific Strategies. G. Molema, D.K.F. Meijer (Eds.). Wiley-VCH, Weinheim, 2001, 275-308.
54. Everts, M., Koning, G.A., Kok, R.J. et al. In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm Res 2003, 20: 64-72.
55. Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D. et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26: 60-70.
56. Chuang, V.T., Kragh-Hansen, U., Otagiri, M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002, 19: 569-77.
57. Beljaars, L., Weert, B., Geerts, A. et al. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 2003, 66: 1307-17.
58. Beljaars, L., Molema, G., Weert, B. et al. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999, 29: 1486-93.
59. Di Stefano, G., Kratz, F., Lanza, M., Fiume, L. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Dig Liver Dis 2003, 35: 428-33.
60. Melgert, B.N., Weert, B., Schellekens, H. et al. The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and Kupffer cells. J Drug Target 2003, 11: 1-10.
61. Harrington, K., Alvarez-Vallina, L., Crittenden, M. et al. Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery? Hum Gene Ther 2002, 13: 1263-80.
62. Vallera, D.A., Jin, N., Baldrica, J.M. et al. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res 2000, 60: 976-84.
63. Chester, J., Ruchatz, A., Gough, M. et al. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol 2002, 20: 256-63.
64. Coukos, G., Makrigiannakis, A., Kang, E.H. et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999, 5: 1523-37.
65. Clohisy, D.R., Ramnaraine, M.L. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 1998, 16: 660-6.
66. Hamada, H., Kobune, M., Nakamura, K. et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005, 96: 149-56.
67. Eklund, J.W., Kuzel, T.M. Denileukin diftitox: A concise clinical review. Exp Rev Anticancer Ther 2005, 5: 33-8.
68. Vallera, D.A., Todhunter, D.A., Kuroki, D.W. et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 2005, 11: 3879-88.
69. Frankel, A.E., Powell, B.L., Hall, P.D. et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002, 8: 1004-13.
70. Johannes, L., Decaudin, D. Protein toxins: Intracellular trafficking for targeted therapy. Gene Ther 2005.
71. Azemar, M., Djahansouzi, S., Jager, E. et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/Her2. Breast Cancer Res Treat 2003, 82: 155-64.
72. Kreitman, R.J., Wilson, W.H., White, J.D. et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (Lmb-2) in patients with hematologic malignancies. J Clin Oncol 2000, 18: 1622-36.
73. Rosenberg, S.A., Yang, J.C., White, D.E., Steinberg, S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 1998, 228: 307-19.
74. Ruef, C., Coleman, D.L. Granulocyte-macrophage colony-stimulating factor: Pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 1990, 12: 41-62.
75. Tsung, K., Meko, J.B., Peplinski, G.R. et al. IL-12 induces T helper 1-directed antitumor response. J Immunol 1997, 158: 3359-65.
76. Penichet, M.L., Dela Cruz, J.S., Shin, S.U., Mortison, S.L. A recombinant IgG3-(IL-2) fusion protein for the treatment of human Her2/Neu expressing tumors. Hum Antibodies 2001, 10: 43-9.
77. Dela Cruz, J.S., Trinh, K.R., Morrison, S.L., Penichet, M.L. Recombinant anti-human Her2/Neu IgGS-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000, 165: 5112-21.
78. Dela Cruz, J.S., Morrison, S.L., Penichet, M.L. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human Her2/Neu extracellular domain plus anti-Her2/Neu IgG3-(IL-2) or anti-Her2/Neu IgGS-(GM-CSF) fusion protein. Vaccine 2005.
79. Halin, C., Rondini, S., Nilsson, F. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002, 20: 264-9.
80. Truter, E.J., Santos, A.S., Els, W.J. Correlation between cell survival, clonogenic activity and micronuclei induction in DMBA-OC-1R cells treated with immunospecific albumin microspheres containing cisplatin and 5-fluorouracil. Cell Biol Int 2002, 26: 505-16.
81. Allen, T.M., Mumbengegwi, D.R., Charrois, G.J. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in marine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005, 11: 3567-73.
82. Krishna, R., Webb, M.S., St. Onge, G., Mayer, L.D. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 2001, 298: 1206-12.
83. Goldenberg, D.M. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993, 94: 297-312.
84. Bethge, W.A., Sandmaier, B.M. Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies. Semin Oncol 2004, 31: 68-82.
85. Winter, J.N. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 2004, 5(Suppl. 1): S22-6.
86. Bergen, M., Chen, R., Gonzalez, R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Exp Opin Biol Ther 2003, 3: 377-84.
87. Galanis, E., Hersh, E.M., Stopeck, AT. et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol 1999, 17: 3313-23.
88. Yoo, G.H., Piechocki, M.P., Oliver, J. et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope 2004, 114: 1871-9.
89. Park, H.S., Cheon, J., Cho, H.Y. et al. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. Gene Ther 2003, 10: 1129-34.
90. Moriuchi, S., Glorioso, J.C., Maruno, M. et al. Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant Ikappabalpha and HSV thymidine kinase. Cancer Gene Ther 2005, 12: 487-96.
91. Sung, M.W., Yeh, H.C., Thung, S.N. et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol Ther 2001, 4: 182-91.
92. Freytag, S.O., Paielli, D., Wing, M. et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002, 54: 873-85.
93. Freund, C.T., Sutton, M.A., Dang, T. et al. Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res 2000, 20: 1359-65.
94. Wahl, R.L. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005, 46(Suppl. 1): 128S-40S.
95. Evens, A.M., Gordon, L.I. Radioimmunotherapy in non-Hodgkin's lymphoma: Trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Clin Lymphoma 2004, 5(Suppl. 1): S11-5.
96. Iznaga-Escobar, N. 188Re direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: Biodistribution, normal organ dosimetry, and toxicology. Nucl Med Biol 1998, 25: 441-7.
97. Lam, M.G., de Klerk, J.M., van Rijk, P.P. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 2004, 31(Suppl. 1): S162-70.
98. Novak-Hofer, I., Schubiger, P.A. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002, 29: 821-30.
99. Macklis, R.M., Kinsey, B.M., Kassis, A.I. et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988, 240: 1024-6.
100. Zalutsky, M.R., Vaidyanathan, G. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000, 6: 1433-55.